Abstract
We have used low doses of mizoribine (MZ) or mycophenolate mofetil (MMF) as induction and maintenance immunosuppressants, but since 2009 have employed a high dose of MZ. We reviewed the efficacy and side effects of MZ compared with MMF. It is difficult to compare graft survivals between these periods because of different patient demographics, though the high dose of MZ cohort showed no significant difference from MMF. High doses of MZ serum to prevent acute rejection episodes as the induction and maintenance therapy. MZ controlled with blood concentrations showed less side effects, suggesting that high MZ doses could be safely used for an induction and maintenance antimetabolite.
Copyright © 2012 Elsevier Inc. All rights reserved.
MeSH terms
-
Adolescent
-
Adult
-
BK Virus / pathogenicity
-
Child
-
Cytomegalovirus Infections / virology
-
Female
-
Graft Rejection / immunology
-
Graft Rejection / prevention & control
-
Graft Survival / drug effects
-
Herpes Zoster / virology
-
Humans
-
Immunosuppressive Agents / administration & dosage*
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / blood
-
Immunosuppressive Agents / pharmacokinetics
-
Japan
-
Kidney Transplantation* / immunology
-
Male
-
Middle Aged
-
Mycophenolic Acid / administration & dosage
-
Mycophenolic Acid / adverse effects
-
Mycophenolic Acid / analogs & derivatives*
-
Polyomavirus Infections / virology
-
Retrospective Studies
-
Ribonucleosides / administration & dosage*
-
Ribonucleosides / adverse effects
-
Ribonucleosides / blood
-
Ribonucleosides / pharmacokinetics
-
Treatment Outcome
-
Young Adult
Substances
-
Immunosuppressive Agents
-
Ribonucleosides
-
mizoribine
-
Mycophenolic Acid